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Abstract
Background: Coagulopathic bleeding is common after cardiac surgery and is associ-
ated with increased morbidity, mortality and healthcare costs. Implementation of 
blood management algorithms in which patients with severe bleeding undergo near- 
patient coagulation testing results in less overall bleeding and transfusion. However, it 
is unknown whether there is additional value from pre- emptive near- patient testing to 
predict whether severe bleeding will occur.
Objectives: To evaluate how well a comprehensive panel of 28 near- patient platelet 
and viscoelastometry tests predict bleeding after cardiac surgery, compared to predic-
tion using baseline clinical characteristics alone.
Methods: Single- center, prospective cohort study in adults undergoing a range of car-
diac surgery procedures. The primary outcome was clinical concern about bleeding 
(CCB), a composite of high blood loss (chest drain volume >600 mL within 6 hours), 
re- operation for bleeding or administration of a pro- haemostatic treatment directed 
by clinician judgement.
Results: In 1833 patients recruited between March 2010 and August 2012, the me-
dian number of abnormal near- patient test results was 5/28 per patient (range 0- 18). 
CCB occurred in 449/1833 patients (24.5%). The c- statistic for a predictive model for 
CCB using only baseline clinical characteristics (baseline-only model) was 0.72 (95% CI 
0.69- 0.75). Addition of near- patient test results to this model (baseline-plus-test model) 
improved the prediction of CCB (c- statistic 0.75 [0.72- 0.77]), but increased the num-
ber of correctly classified patients by only 18 (0.98%).
Conclusions: Near- patient coagulation testing predicts bleeding in cardiac surgery pa-
tients, but offers little improvement in prediction compared to baseline clinical charac-
teristics alone. trial registration: ISRNCTN 20778544 (http://www.isrctn.com/).
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blood coagulation, blood component transfusion, cardiac surgery, hemorrhage, point-of-care systems
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1  | INTRODUCTION
Severe bleeding caused by coagulopathy is common after cardiac sur-
gery and frequently requires large volume red blood cell (RBC) trans-
fusion (>4 units) or emergency re- operation.1,2 Severe bleeding, RBC 
transfusion and re- operation are independently associated with organ 
failure, sepsis and death.3–5 The provision of RBC and other blood 
components for cardiac surgery patients also has significant health 
care costs, and accounts for 10- 15% of the UK blood supply.6,7
Near- patient coagulation testing using viscoelastometry or rapid 
platelet function analysers detects the common sub- types of coag-
ulopathy associated with cardiac surgery in a clinically useful times-
cale.8,9 Several small, single- center, randomized controlled trials (RCTs) 
in cardiac surgery have shown that when compared to conventional 
laboratory testing or clinician judgement alone, near- patient testing 
reduced transfusion of RBC10,11 or non- RBC blood components.10–15 
In a multicenter RCT of more than 7400 patients, implementation of 
a blood management algorithm incorporating near- patient tests, re-
sulted in reduced RBC transfusion, platelet transfusion and overall 
bleeding.16 In this trial, near- patient test results were used to direct 
targeted treatments for coagulopathy only in patients who had already 
developed severe bleeding.16
Previous studies have also shown that some near- patient test re-
sults from before the start, or immediately after the end of cardiac 
surgery also enable prediction of postoperative bleeding.17–23 This 
suggests an alternative blood management strategy in which near- 
patient testing is performed pre- emptively before the highest risk 
period for severe bleeding in the immediate post- operative period. 
This is an attractive clinical strategy since identification of patients at 
the highest risk of bleeding could potentially enable selective targeted 
treatments to prevent severe bleeding starting. Predictive near- patient 
testing has been incorporated into several blood management algo-
rithms evaluated in several previous RCTs, usually as a single step for 
selection of preventative treatments10,12,13,15 or in combination with 
later diagnostic near- patient testing in patients who develop bleeding 
despite preventative treatments.11
Blood management algorithms incorporating near- patient tests 
are recommended in US and European practice guidelines24–26, and 
are used widely.27 However, there is poor consensus about the best 
algorithm design, particularly whether near- patient tests should be 
performed in response to severe bleeding, or whether there is ad-
ditional value in pre- emptive testing to help prevention of bleeding. 
We have performed a large prospective observational cohort study 
(Coagulation and Platelet Laboratory Testing in Cardiac Surgery 
[COPTIC] study; ISRCTN 20778544) to evaluate coagulation testing 
in a range of cardiac surgery procedures. In order to clarify the role 
of near- patient testing, we now report an analysis of how well near- 
patient tests predict bleeding, compared with prediction using patient 
clinical and procedural characteristics alone.
2  | METHODS
2.1 | Study design and patients
The COPTIC study was a single center, observational cohort study 
in which patients undergoing cardiac surgery at the Bristol Heart 
Institute were recruited in accordance with a pre- specified protocol 
and in accordance with a UK NHS Research Ethics Committee ap-
proval (09/H0104/53). All patients aged over 18 years undergoing any 
non- emergency cardiac surgical procedure were eligible unless they 
were prisoners or were unable to consent due to mental incapacity.
2.2 | Care of patients and classification of pro- 
haemostatic treatments
All participating patients gave written consent before surgery and 
were managed using standard anesthetic and surgical care pathways. 
Protamine (1 mg per 100 units of heparin) was given to reverse hepa-
rin anticoagulation immediately at the end of surgery. For procedures 
other than off- pump coronary artery bypass grafting (CABG), patients 
received anti- fibrinolytic drugs and additional protamine after the re-
turn of heparinized blood from the cardiopulmonary bypass circuit. 
These pro- haemostatic treatments were classified as directed by stand-
ard care because the decision to treat was made before the start of 
surgery. Some patients also received pro- haemostatic treatment with 
fresh frozen plasma, cryoprecipitate, platelets, recombinant Factor 
VIIa, fibrinogen concentrate, and additional anti- fibrinolytic drugs or 
protamine because severe bleeding was judged to have started. These 
treatments were classified as pro-haemostatic treatments by clinical 
judgement.
2.3 | Baseline characteristic and near- patient 
testing predictors
Patient clinical characteristics, surgical procedure and the results of 
conventional laboratory tests from pre- operative assessments were 
recorded from electronic hospital records. Near- patient tests were 
performed on a ‘pre- operative sample’ obtained at induction of 
Essentials
• Near-patient testing improves coagulopathy diagnosis in cardiac surgery patients with severe bleeding.
• We investigated how well pre-emptive near-patient testing predicted severe bleeding.
• Severe bleeding could be predicted using both near-patient tests and patient clinical characteristics.
• Near-patient test results gave little additional predictive value over clinical characteristics alone.
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anesthesia and on a ‘post- operative sample’ obtained at the end of 
surgery, after protamine for heparin reversal but before chest closure 
and insertion of chest drains.
All samples were tested using a multiple electrode aggregometry 
platelet function analyser (Multiplate; Roche Diagnostics, Rotkreuz, 
Switzerland, TRAP- test, ASPI- test,, and ADP- test reagents) and with 
adrenaline (ADR 100 mg mL−1). The post- operative samples were also 
tested using a ROTEM delta thromboelastometer (TEM International 
GmbH, Munich, Germany; EXTEM, INTEM, HEPTEM, and FIBTEM 
reagents) and a TEG 5000 Thromboelastograph (Haemonetics Corp., 
Braintree, MA, USA; kaolin [CK] and kaolin/heparinise [CKH] re-
agents). Test results were unavailable to the clinicians responsible for 
the care of the patients.
2.4 | Outcomes
The primary outcome was clinical concern about bleeding (CCB) after 
cardiac surgery, defined as a composite of any of the following: (i) a 
chest drain volume greater than 600 mL at 6 hours after admission to 
the cardiac intensive care unit (CICU); (ii) any re- operation for bleed-
ing during the hospital stay in which a surgical cause of bleeding was 
not identified; or, (iii) any pro-haemostatic treatment by clinical judge-
ment from the time of the post- operative blood sample until 12 hours 
after CICU admission. Pro- haemostatic treatments directed by clinical 
judgement were included in the primary outcome because these are 
the only reliable indicator of severe bleeding that occurs: (i) after the 
end of surgery but before chest drain insertion, or, (ii) after chest drain 
insertion but which is successfully reversed before the 600 mL chest 
drain volume threshold is reached.
The secondary outcomes were RBC transfusion, myocardial in-
farction (MI), stroke, acute kidney injury (AKI), sepsis and mortality 
(Table S1). The study observation period was the duration of hospital 
admission.
2.5 | Selection of predictors
The baseline characteristics age, sex, diabetes, type of procedure, anti- 
platelet drugs, surgical priority, estimated glomerular filtration rate, 
haematocrit, platelet count, and body mass index were selected as 
candidate predictors of CCB, before generation of predictive models 
(Table S2). Since a large number of different surgical procedures were 
performed in the study population, patients were classified into 12 
categories depending on the type of procedure (CABG, CABG+valve, 
valve only, other high risk bleeding procedure) and pre- operative anti- 
platelet drugs (no anti- platelet drugs, aspirin alone and aspirin+P2Y12 
blocker sub- grouped according to duration of omission of P2Y12 
blocker before surgery: Table S2).
The candidate near- patient test predictors were a panel of 28 
results from pre- operative or post- operative MEA platelet function 
analysis or from post- operative ROTEM or TEG viscoelastometry 
(Table S3). The viscoelastometry tests included measures of the speed 
of clot formation (INTEM/EXTEM clot time and α angle; CK R time), 
clot strength (INTEM/EXTEM maximum clot firmness; CK maximum 
amplitude), fibrinogen component of clot strength (FIBTEM maximum 
clot firmness), heparin effect (INTEM clot time - HEPTEM clot time 
and CK R time - CKH R time) and fibrinolysis (INTEM/EXTEM mini-
mum lysis; CK lysis 60), which are previously reported coagulopathies 
after cardiac surgery.8,9 The MEA platelet function analyzer ADP- test 
and ASPI- test results measures platelet dysfunction associated with 
P2Y12 blockers and aspirin, respectively.
28 The EXTEM maximum clot 
firmness - FIBTEM maximum clot firmness and TRAP- test results were 
selected to measure global platelet dysfunction function.11,16 Test re-
sults were incorporated into predictive models for CCB as continuous 
variable. However, in order help describe the distributions for the test 
results, each result was also classified as above or below a 95% ref-
erence interval obtained by from 42 healthy volunteers (median age 
48 years, 68% male), determined locally using the same analyzers as 
the main study.
2.6 | Statistical analysis
In order to compare predictive models that incorporated near- patient 
test results with alternative models that included the baseline char-
acteristics, the analysis population was defined as all patients with 
complete data for all predictors. Bias due to this constraint was in-
vestigated by calculating standardized mean differences (SMD)29 to 
compare the analysis population with those excluded because of miss-
ing data.
Logistic regression was used to develop predictive models and to 
estimate associations between CCB or secondary outcomes and the 
baseline characteristics (baseline-only model) or alternative models 
that also included near- patient test results (baseline-plus-test models). 
The near- patient tests were further evaluated post hoc, with a model 
that included only the best- fitting near- patient test results (test-only 
model). The best baseline-only, baseline-plus-test, and test-only models 
were selected as the models with the highest c- statistic. Predictive 
value was also expressed as the proportion of patients correctly clas-
sified as CCB or no CCB, where those with a predicted probability of 
CCB ≥0.5 were classified as CCB. For all models, multivariable frac-
tional polynomial techniques were used to investigate the linearity 
of terms. Model fit was assessed with Hosmer- Lemeshow goodness- 
of- fit tests and individual contributions to the models were evaluated 
using likelihood ratio tests.
For the best baseline-plus-test model, three sensitivity analy-
ses considered alternative formulations of the primary outcome 
(Table S4). In the first two sensitivity analyses, patients who were 
classified as CCB solely because of a pro-haemostatic treatment by 
clinical judgement were either (i) excluded from analysis (SA1); or (ii) 
reclassified as no CCB (SA2). In a third post hoc sensitivity analysis, 
patients classified as CCB solely because they were transfused with 
1- 2 units of plasma or with 1 unit of platelets, were reclassified as 
no CCB (SA3).
The c- statistics from the primary outcome models were internally 
validated by bootstrapping with 1000 replicates and cross- validated 
by removing one observation and then using the remaining analysis 
population to create models that generated the predicted probability 
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of CCB for that one observation. After repeating the process for each 
observation, the predicted probabilities were used to build receiver 
operator characteristic curves and to calculate c- statistics. All analyses 
were performed in STATA (version 14.0; STATA Corp, College Station, 
TX, USA).
3  | RESULTS
3.1 | Study population and primary outcome
A total of 3638 patients were identified as eligible between March 
2010 and August 2012, of which 2541 (69.8%) provided consent to 
participate (Fig. 1). The analysis population comprised 1833 patients 
(72.1% of consented) with complete baseline characteristics and near- 
patient test results. This population had median age 68.9 years (range 
18.7- 91.96) and included 1389 males (75.8%). Most of the analysis 
population underwent CABG with aspirin (40.2%), valve replacement 
with no anti- platelet drugs (16.4%), or valve replacement with aspirin 
(7.3%; Table 1). Compared to the analysis population, the 708 patients 
excluded due to missing data had a smaller proportion of patients 
who underwent CABG with aspirin (31.7% vs 40.2%; SMD 0.18) and 
a higher proportion who underwent valve replacement with aspirin 
(10.3% vs 7.3%; SMD 0.11). For all the other baseline characteristics, 
the SMDs were less than 0.10, indicating that the groups were similar 
(Table S5).30
The primary outcome of CCB occurred in 449 (24.5%) of the 
analysis population, with 182 (9.7%) patients having more than one 
qualifying component. Considering the components separately, 
362 (80.6%) of patients with CCB received a pro- haemostatic 
treatment by clinical judgement, 244 (54.3%) had a chest drain 
volume greater than 600 mL and 57 (12.7%) had re- operation for 
bleeding (Fig. S1).
3.2 | Near- patient coagulation test results
When compared to a 95% reference interval (RI) from a group of 
healthy controls not receiving anti- platelet drugs, the analysis popu-
lation had an overall median of 5 abnormal test results per patient 
(range 0/28- 18/28). The most commonly abnormal test results were 
reduced platelet function with the ASPI- test (76.1% pre- operative 
results below RI; 92.1% post- operative results below RI), adrenaline 
(84.4% pre- operative results below RI; 80.3% post- operative below 
RI), and with the ADP- test (24.5% pre- operative results below RI; 
55.1% post- operative results below RI; Table S6). Abnormal viscoe-
lastometry tests were less common (median 0 abnormal results per 
patient; range 0/28- 12/28), but included reduced ROTEM INTEM 
α- angle (15.3% post- operative results below RI) and FIBTEM maxi-
mum clot firmness (12.1% post- operative results below RI) and re-
duced TEG maximum amplitude (12.4% postoperative results below 
RI; Table S6). The distributions of the near- patient test results in the 
F IGURE  1 Study flow diagram
3638 identified as eligible
2541 consented
2463 with at least one blood sample
1833 in final analysis dataset
(complete data for all baseline characteristics and
test results)
250 outside usual working hours
317 not approached
530 did not consent
5 no cardiac procedure
73 no samples taken
(69.8% of eligible)
(96.9% of consented)
(72.1% of consented)
28 no pre-operative smaples taken
63 incomplete lab results for pre-operative sample
175 incomplete baseline characteristics
23 no post-operative samples taken
26 protocol violations (sample taken at incorrect time)
315 incomplete lab results for post-operative sample
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patients with, and without the primary outcome of CCB are shown in 
Fig. S2.
3.3 | Prediction of CCB using baseline characteristics
Baseline characteristics relating to sex, diabetes, procedure/anti- 
platelet drugs, haematocrit, platelet count, and body mass index were 
statistically significant independent predictors of CCB. Most of the 
variation in CCB was accounted for by procedure/anti- platelet drugs. 
CABG with aspirin was the largest group and was the reference cat-
egory. Compared with this group, CABG+valve and valve procedures 
in patients receiving dual anti- platelet treatment (aspirin plus P2Y12 
blocker within 7 days or less of surgery) conferred the highest odds of 
CCB (Fig. 2, Table 2). The predictive model for CCB using the baseline 
characteristics (baseline-only model), had a c- statistic of 0.72 (0.69- 
0.75; Fig. 3, Table S7) and correctly classified 76.8% of patients as 
CCB or no CCB. The results of the internal validation and goodness of 
model fit are shown in Table S7.
3.4 | Prediction of CCB using baseline 
characteristics and near- patient test results
Alternative predictive models incorporating near- patient test results 
altered the prediction of CCB compared to the baseline- only model 
(Table S8). The best baseline-plus-test model incorporated baseline 
characteristics plus the post- operative MEA platelet function results 
with the ASP- test and adrenaline and the TEG maximum amplitude 
(Table S9), and had a c- statistic of 0.75 (0.72- 0.77; P=.001 compared 
to baseline-only model; Fig. 3, Table S8). Application of the best base-
line-plus-test model resulted in correct reclassification of 63 patients 
(49 who had CCB who were initially classified as no CCB and 14 who 
did not have CCB but were initially classified as no CCB). However, 
45 patients were incorrectly reclassified (6 who had CCB who were 
initially classified as CCB and 39 who did not have CCB who were ini-
tially classified as no CCB). Therefore, the net improvement of correct 
classification was only 18/1833 patients (0.98%). The internal valida-
tion and goodness of model fit are shown in Table S7.
3.5 | Sensitivity analyses
After excluding (SA1) or re- classifying (SA2) 181 patients who were 
classified as having CCB solely because they had received a pro- 
haemostatic treatment by clinician judgement (SA1: CCB in 268/1652 
[16.2%]; SA2: CCB in 268/1833 [14.6%]), the c- statistics of the best 
baseline-plus-test model did not differ from the original CCB definition 
(Table S8). In the post hoc sensitivity analysis (SA3), in which patients 
who received only small volume plasma or platelet transfusions were 
reclassified as no CCB (CCB in 348/1832 [19.0%]), there was also no 
difference in c- statistic (Table S8).
3.6 | Prediction of CCB using only near- patient 
test results
The best test-only model for CCB, which included only the near- 
patient test results without baseline characteristics, had a c- statistic 
of 0.71 (0.69- 0.74; Fig. 4, Table S7).
3.7 | Secondary outcomes
A total of 660/1797 (36.7%) of the analysis population received 
at least a one unit RBC transfusion, and 96/1796 (5.4%) received 
more than four units before CICU discharge. The prevalence of all 
the secondary outcomes are shown in Table 3 and their relation-
ships with the near- patient test results in Table S10. Inclusion of 
near- patient test results into baseline-only models generated for 
each secondary outcome marginally improved prediction for any 
post- operative RBC transfusion (c- statistic 0.85 [0.83- 0.87] for 
baseline-plus-test vs 0.83 (0.81- 0.85) for baseline-only; P<.001) and 
for sepsis (c- statistic 0.74 [0.70- 0.79] for baseline-plus-test vs 0.70 
[0.65- 0.75] for baseline-only; P=.01). Inclusion of near- patient test 
results did not improve the c- statistics for the other secondary out-
comes (Table 3).
TABLE  1 Baseline characteristics of the analysis population 
(n = 1833)
Age (median, range) 68.9 (18.7, 91.9)
Sex; n (%) male 1389 (75.8%)
Diabetes; n (%) yes 380 (20.7%)
Procedure and anti- platelet drugs; n (%)
CABG: ASP 737 (40.2%)
CABG: no APT 61 (3.3%)
CABG+valve: no APT 66 (3.6%)
Valve: no APT 301 (16.4%)
CABG+valve: ASP 127 (6.9%)
Valve: ASP 133 (7.3%)
CABG: DAPT (0- 2 days) 98 (5.3%)
CABG: DAPT (3- 5 days) 114 (6.2%)
CABG: DAPT (6- 7 days) 88 (4.8%)
CABG+valve: DAPT (≤7 days) 14 (0.8%)
Valve: DAPT (≤7 days) 5 (0.3%)
Other high risk procedure 89 (4.9%)
Operative priority; n (%)
Elective 1204 (65.7%)
Urgent 629 (34.3%)
eGFR (mL/min/1.73 m2; median, range) 73.7 (8.0, 214.6)
Pre- operative haematocrit (%; median, 
range)
36.0 (19.0, 53.00)
Pre- operative platelet count  
(×109/L; median, range)
205.0 (43.0, 561.0)
Body mass index (kg/m2; mean, SD) 28.0 (4.7)
CABG, coronary artery bypass grafting; Valve, valve replacement; ASP, as-
pirin or aspirin plus P2Y12 blocker stopped more than 7 days before sur-
gery; APT, any anti- platelet drugs; DAPT, aspirin plus P2Y12 blocker 7 or 
less days before surgery shown with duration of omission of P2Y12 blocker 
before surgery shown in brackets; eGFP, estimated glomerular filtration 
rate; SD, standard deviation.
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4  | DISCUSSION
In this large, prospective, observational cohort study we evaluated 
whether comprehensive near- patient coagulation testing improved 
prediction of severe bleeding after cardiac surgery when compared 
with prediction based on patient baseline characteristics alone. The 
first main finding was that the baseline characteristics of patients 
enabled a clinically useful level of prediction of the primary outcome 
of CCB (baseline-only model). Abnormal near- patient tests were com-
mon in the analysis population. However, including the test results 
into a predictive model that already contained baseline characteris-
tics (baseline-plus-test model) resulted in the correct reclassification 
of only 0.98% of patients as either CCB or no CCB, suggesting mini-
mal clinical benefit. Including near- patient test results into baseline-
only models for the secondary outcomes of blood component use, 
post- operative complications and mortality also gave little improve-
ment in prediction.
4.1 | Comparison with other studies
The baseline-only model developed in the analysis population ena-
bled the correct classification of 76.8% of patients as either CCB or 
no CCB. This is consistent with several previous studies in which 
demographic details, comorbidities, conventional pre- operative 
laboratory test results31–35, and procedural characteristics31,35 
contributed to prediction of RBC transfusion. The baseline-only 
model confirmed that exposure to anti- platelet drugs before cardiac 
surgery is also a strong predictor of post- operative bleeding.17,20 
We also showed that for patients having CABG, aspirin plus a P2Y12 
blocker stopped for less than 2 days increased the risk of severe 
bleeding fourfold compared to aspirin alone. However, there was no 
increased risk if the P2Y12 blocker was stopped for 6 to seven days. 
This confirms the empiric advice in current practice guidelines36, 
that stopping P2Y12 blockers for at least 5 days achieves the great-
est reduction in bleeding risk.
A unique feature of the COPTIC study was the comprehensive 
panel of near- patient tests used to detect coagulopathy. One striking 
finding was that the analysis population had a median of 5/28 test 
results per patient that were abnormal (range 0- 18) when compared to 
healthy control reference intervals, which were similar in our study to 
previously published reference intervals.37–39 By far the most common 
abnormalities were reduced platelet function with the ASPI- test and 
adrenaline reagents. Since both reagents are sensitive to dysfunction 
of the platelet cyclooxygenase pathway28,40, this finding is consistent 
with the high proportion of patients receiving aspirin (approximately 
75%). Reduced platelet function with the ADP- test was less common, 
reflecting the lower number of patients with any exposure to P2Y12 
blockers before surgery (approximately 20%).28
Compared to the platelet function tests, abnormal viscoelastome-
try tests were less common (median 0/28 abnormal tests per patient; 
range 0- 12), but included reduced ROTEM INTEM α- angle, ROTEM 
F IGURE  2 Baseline characteristics and clinical concern about bleeding. Data are odds ratios with 95% confidence intervals for clinical 
concern about bleeding. Odds ratios are for male vs female, presence of diabetes vs no diabetes, procedure type/anti- platelet drug group vs 
CABG with ASP, and urgent vs elective priority. Odds ratios are adjusted for other factors in the table and for whether the patient was in an 
interventional study at our center. CABG, coronary artery bypass grafting; Valve, valve replacement; ASP, aspirin alone or aspirin plus P2Y12 
blocker stopped for longer than 7 days before surgery; APT, any anti- platelet drugs; DAPT, aspirin plus recent P2Y12 blocker stopped 7 days or 
less before surgery, with duration of omission of P2Y12 blocker indicated in brackets. Odds ratios and 95% confidence intervals are also reported 
in Table S7
1 50 150
Odds ratios (95% CI)
Age (per 10 yrs)
Males
Diabetes
CABG: ASP
CABG: no APT
CABG+valve: no APT
CABG+valve: ASP
Valve: no APT
Valve: ASP
CABG: DAPT (0-2 days)
CABG: DAPT (3-5 days)
CABG: DAPT (6-7 days)
CABG+valve: DAPT (≤7 days)
Valve: DAPT (≤7 days)
Other high risk procedures
Elective priority
Urgent priority
Pre-operative eGFR ÷ 100
Pre-operative haematocrit ÷ 10
Pre-operative platelet count ÷ 100
Body Mass Index ÷ 10
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FIBTEM maximum clot firmness and reduced TEG maximum clot firm-
ness. Together, these suggest impaired clot formation and fibrinogen 
component of clot strength, both previously reported after cardiac 
surgery.41,42 Near- patient test results indicating reduced thrombin 
generation, heparin- effect or hyperfibrinolysis were uncommon in the 
analysis population.
Although addition of near- patient test results to the baseline-only 
model gave a statistically significant increase in prediction, there was 
only a small benefit when expressed as the proportion of patients cor-
rectly classified as CCC or no CCB. In a post hoc analysis, a test-only 
model also predicted CCB with a similar c- statistic to the baseline-only 
model. Therefore, the failure of near- patient tests to substantially im-
prove prediction does not indicate that testing per se does not predict 
bleeding. Instead, it is likely that most of the predictive information 
from near- patient testing is already provided by the patients’ base-
line characteristics. The abundance of abnormal platelet function test 
results in the analysis population suggests that this is particularly rele-
vant for exposure anti- platelet drugs.
4.2 | Strengths and weaknesses
The main strength of the COPTIC study was the low risk of bias ena-
bled by (i) enrolment of unselected patients having a range of car-
diac surgery procedures, (ii) enrolment of nearly 70% of all eligible 
patientsand, and (iii) standardized testing of blood samples remote 
from surgery so that results could not influence interventions or out-
comes. The COPTIC study is also by far the largest and most com-
prehensive analysis of the predictive value of near- patient tests in 
cardiac surgery.
A further strength was our definition of CCB as a composite end-
point to reflect severe bleeding. Our definition included high blood 
loss into chest drains and reoperation for bleeding, similar to other 
TABLE  2 Baseline characteristics and CCB
No CCB; n=1384 CCB; n=449 Adjusted ORa P- value
Age (median, range) 68.1 (18.7, 91.9) 71.3 (19.5, 91.4) 1.01 (1.00, 1.02) .14
Sex; n (%) male 1029 (74.3%) 360 (80.2%) 0.57 (0.42, 0.78) <.001
Diabetes; n (%) 314 (22.7%) 66 (14.7%) 0.57 (0.41, 0.79) .001
Procedure and anti- platelet medication; n (%)
CABG: ASP 619 (44.7%) 118 (26.3%) 1.00 <.001
CABG: no APT 50 (3.6%) 11 (2.4%) 1.19 (0.59, 2.37)
CABG+valve: no APT 47 (3.4%) 19 (4.2%) 1.73 (0.95, 3.15)
Valve: no APT 239 (17.3%) 62 (13.8%) 1.26 (0.86, 1.84)
CABG+valve: ASP 68 (4.9%) 59 (13.1%) 3.97 (2.59, 6.10)
Valve: ASP 90 (6.5%) 43 (9.6%) 2.16 (1.37, 3.39)
CABG: DAPT (0- 2 days) 58 (4.2%) 40 (8.9%) 4.18 (2.59, 6.75)
CABG: DAPT (3- 5 days) 76 (5.5%) 38 (8.5%) 2.52 (1.59, 4.00)
CABG: DAPT (6- 7 days) 72 (5.2%) 16 (3.6%) 1.29 (0.71, 2.33)
CABG + valve: DAPT (≤7 days) 4 (0.3%) 10 (2.2%) 10.18 (3.02, 34.33)
Valve: DAPT (≤7 days) 2 (0.1%) 3 (0.7%) 5.89 (0.93, 37.47)
Other high risk procedure 59 (4.3%) 30 (6.7%) 2.29 (1.36, 3.88)
Priority n (%)
Elective 928 (67.1%) 276 (61.5%) 1.00 .09
Urgent 456 (32.9%) 173 (38.5%) 1.26 (0.97, 1.64)
Pre- operative eGFR (mL/
min/1.73 m2; median, range)
75.7 (8.0, 214.6) 68.4 (12.0, 196.6) 1.00 (0.99, 1.00) .20
Pre- operative haematocrit (%; 
mean, SD)
36.1 (4.2) 35.4 (4.8) 0.97 (0.94, 0.99) .01
Pre- operative platelet count 
(×109/L; median, range)
207.5 (62.0, 561.0) 196.0 (43.0, 548.0) 1.00 (0.99, 1.00)b <.001
Body mass index (kg/m2; median, 
range)
27.7 (16.5, 55.5) 26.6 (16.2, 64.5) 0.96 (0.93, 0.99) .004
CABG, coronary artery bypass grafting; Valve, valve replacement; CABG+valve, combined CABG and valve replacement; ASP, pre- operative aspirin; no 
APT, no pre- operative anti- platelet medication; DAPT, aspirin+P2Y12 blocker shown with duration of omission of P2Y12 blocker before surgery; eGFR, 
estimated glomerular filtration rate.
aOdds ratios are adjusted for all other factors in the table, and for whether the participant was included in an interventional study at our center. The P values 
were calculated from this multivariate analysis.
bThe absolute OR for platelet count expressed as ×109/L is 0.9961738 (95% CI 0.9941638, 0.9981878).
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cardiac surgery studies.43 However, we also included pro-haemostatic 
treatments by clinical judgement administered in response to observed 
severe bleeding, to identify patients that would not be captured with 
the other endpoint definitions. It is a potential criticism that some 
pro-haemostatic treatments by clinicial judgement may have been 
given before severe bleeding was observed, resulting in misclassifica-
tion of patients as CCB. However, in sensitivity analyses using more 
conservative definitions of severe bleeding for the primary outcome, 
the main findings remained consistent.
It is also a potential weakness of the study that some participants 
had one or more items of missing data, usually because of quality con-
trol failure of one or more tests or because of insufficient evaluable 
blood samples. To address this limitation, we decided to carry out a 
‘complete case analysis’ in preference to imputing missing data be-
cause the study had adequate power when analyzing only those par-
ticipants with complete data. The standardized mean differences of 
TABLE  3 Performance of predictive models for the secondary outcomes
Secondary outcome Frequency
Baseline-only model c- statistic 
(95% CI)
Baseline-plus-test model c- statistic 
(95% CI) P value
RBC intra- op/post- op (0 vs 
≥1 u)
660/1797 (36.7%) 0.85 (0.83- 0.87) 0.85 (0.83- 0.87) .58
RBC intra- op/post- op (≤4 vs 
>4 u)
96/1796 (5.4%) 0.85 (0.81- 0.89) No change –
RBC post- op (0 vs ≥1 u) 581/1795 (32.4%) 0.83 (0.81- 0.85) 0.85 (0.83- 0.87) <.001
RBC post- op (≤4 vs >4 u) 59/1802 (3.3%) 0.83 (0.78- 0.88) 0.84 (0.78- 0.89) .44
Death 34/1833 (1.9%) 0.84 (0.77- 0.91) No change –
Myocardial infarction 19/1828 (1.0%) 0.68 (0.55- 0.82) No change –
Stroke 19/1828 (1.0%) 0.81 (0.72- 0.90) No change –
Acute kidney injury 819/1833 (44.7%) 0.76 (0.74- 0.78) 0.76 (0.74- 0.79) .08
Sepsis 104/1826 (5.7%) 0.70 (0.65- 0.75) 0.74 (0.70- 0.79) .01
RBC, red blood cell transfusion. C- statistics are shown for the baseline-only model that incorporates the demographic and clinical characteristics of the 
patients and the best baseline-plus-test model that also incorporates near- patient laboratory test results. Only pre- operative test results were considered 
for the intra- op/post- op outcomes.
F IGURE  3 Receiver operator characteristics curve for the 
baseline-only and best baseline-plus-test models for prediction 
of clinical concern about bleeding. This baseline-plus-test model 
incorporated near- patient test result from post- operative TEG and 
post- operative MEA analyzers
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the baseline characteristics of the excluded population were similar to 
the analysis population, indicating that it is unlikely that this exclusion 
strategy introduced bias.
4.3 | Clinical impact of study findings
Current practice guidelines support incorporating near- patient co-
agulation testing into blood management algorithms for cardiac sur-
gery.24–26 However, these guidelines do not distinguish between the 
use of near- patient tests to inform treatment selection after patients 
develop severe bleeding, and the use of pre- emptive testing to predict 
bleeding and to direct preventative treatments.
The results of the COPTIC study provide general support for near- 
patient testing to assist blood management in cardiac surgery because 
our findings confirm that currently available near- patient analyzers 
distinguish different coagulopathies in this setting. Identifying high 
bleeding risk patients before bleeding occurs so that targeted pre-
ventative treatments can be given is an attractive potential clinical 
strategy. We have shown that bleeding can be predicted to a modest 
extent by considering clinical baseline characteristics that are readily 
available before the start of surgery, and that there is unlikely to be any 
additional benefit from pre- emptive near- patient testing in unselected 
patients.
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